The Royal Children's Hospital Melbourne 50 Flemington Road Parkville Victoria 3052 Australia TELEPHONE +613 9345 5522 www.rch.org.au



Participant Information Sheet/Consent Form – Parent/Guardian

Title	Safety study of sibling cord blood cell infusion to children with cerebral palsy
Short Title	Stem Cells in Umbilical Blood Infusion for CP (SCUBI-CP)
HREC ID	HREC/14/RCHM/38
Principal Investigator	Prof Dinah Reddihough
Location	The Royal Children's Hospital Melbourne

1 Introduction

This is an invitation for your child to take part in this research project because he or she has cerebral palsy (CP). The research project is testing a possible new treatment for cerebral palsy. The new treatment is called sibling cord blood cell infusion.

This Participant Information Sheet/Consent Form tells you about the research project. It explains the tests and treatments involved. Knowing what is involved will help you decide if you want your child to take part in the research.

Please read this information carefully. Ask questions about anything that you don't understand or want to know more about. Before deciding whether or not your child can take part, you might want to talk about it with a relative, friend or your child's local doctor.

Participation in this research is voluntary. If you do not wish your child to take part, they do not have to. Your child will receive the best possible care whether or not they take part.

If you decide you want your child to take part in the research project, you will be asked to sign the consent section. By signing it you are telling us that you:

· Understand what you have read

· Consent to your child taking part in the research project

· Consent for your child to have the tests and treatments that are described

• Consent to the use of the cord blood you have in storage from a brother or sister to your child who has cerebral palsy

• Consent to the use of your child's personal and health information as described.

You will be given a copy of this Participant Information Sheet and Consent Form to keep.



Our Values Unity, Respect, Integrity, Excellence

Master Parent/Guardian Information Sheet/Consent Form 15/03/17, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 1 of 16

2 What is the purpose of this research?

Cord blood is the blood collected from the umbilical cord when a child is born. It contains different types of cells, including a small number of stem cells.

Cord blood cell infusion is approved in Australia to treat disorders (conditions) that affect the blood. However, it is not approved as a treatment for cerebral palsy. Therefore, it is an experimental treatment for cerebral palsy. This means that it must be tested to see if it is safe for children with cerebral palsy.

This research study is the first step in a long process of finding out if cord blood cell infusion into a vein can help children with cerebral palsy (CP). We aim to find out if the cord blood cell infusion is safe. Depending on the results of this small safety study, we will need further studies to test the infusion on more people to find out if it does help children with CP.

This safety trial will include infusion with cord blood cells from your child's brother or sister if they match with your child's blood.

3 What does participation in this research involve?

Study length

If you consent to your child participating in this study, there will be about 9 visits with the study team. These visits will mostly be at the hospital, although some may be at your local doctor's clinic if you choose.

Before you consent, you may want to think about whether you and your family are able and willing to commit to the time and travel this study will take.

From the time that you consent, the study will take 14 months or more of your family's involvement.

Screening

We will not start your child in this study until you have signed the consent form and we think that your child is eligible for the study. To find out if your child is eligible, we first need to know if your child has cerebral palsy, whether your child has any disorders of the immune system, and whether any of your children have cord blood currently in storage.

Although your child may be eligible to take part in the study, they may not be able to participate if the study doctor does not think that the cord blood cell infusion is appropriate for your child. For example, this might happen if your child is unhealthy or becomes unwell.

If your child has sibling cord blood in storage, we will find out whether or not the sibling cord blood matches your child with cerebral palsy. <u>Only 1 out of 4 siblings have matching blood. This means that 3 out of 4 children *cannot use* their sibling's blood. If the blood matches and is usable, your child will receive the cord blood cells in an infusion. Once the trial is full, your child will not be able to take part in the study. If the blood does not match, your child is unable to have those cord blood cells in their body. It is much more likely that your child will have to leave the study than to receive cord blood cells.</u>

If your child is not able to take part in the study because the study is full, the study doctor will phone you to tell you whether the cord blood matches or not.

Visits and Procedures

The table below details the visits that are needed as part of this project and what will happen at each visit.

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 2 of 17

	Visit 1 (Screening)	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9
Visit time (hours):	1	5	9	1	1	1	2	1	4
Where:	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital, community	Hospital
Sign consent form	✓								
Blood samples	✓	✓	✓	✓	✓	✓	✓		
Sibling blood sample		*							
Physical examination		✓		✓		✓	✓	✓	✓
CP assessment		✓							
Gross motor function		✓					✓		✓
assessment									
Upper limb assessment		✓					✓		✓
Intelligence assessment		✓							✓
Quality of Life		✓					✓		✓
questionnaire									
Parent questionnaire		✓							✓
Cord blood infusion			✓						
Medical assessment			✓	~	✓	✓	✓	✓	

Visits 1-4 and 6, 7 and 9 must take place at the hospital. Visit 5 can be completed by the assessment team in your home, and visit 8 can be conducted by your local paediatrician if it is difficult for you to come to the hospital.

Visit 2 can be quite tiring, so we will make sure your child takes regular breaks. If necessary we can split this visit over two days.

Blood samples

Blood will be collected at most visits. Section 10 below describes how much blood will be taken at each visit, what it will be tested for, where it is tested and what happens to the samples after testing.

* If your child has sibling cord blood in storage, we will try to find out not only whether the cells match, but also whether the blood groups match. If we cannot get all the information we need from the cord blood that is in storage, we may need to ask the sibling to give a blood sample. We will tell you if it is necessary to bring the sibling for study visit 2, and what would be involved.

Physical examination

This will involve listening to your child's heart and lungs, feeling the abdomen, taking your child's pulse and respiratory rates, confirming neurological signs including assessing muscle tone and reflexes, and checking your child's skin. The doctor will take a photo of your child's skin to compare with the skin's appearance after the infusion, to help the doctor know whether your child's skin changes during the study.

CP assessment

We will assess your child's CP using some standard tests including the Gross Motor Function Classification Scheme (GMFCS), Australian Spasticity Assessment Scale (ASAS) and the Manual Assessment Classification Scheme (MACS).

Medical assessment

This is to check your child for any reactions following the infusion. It includes questions about your child's general health and may be conducted in person or by phone. If the doctor needs to see your child in person after these questions, we may need to arrange an extra visit for your child to come to the hospital.

Gross Motor Function assessment

We will document your child's motor abilities. A digital video recording of your child will be made to help with the assessment.

Upper Limb assessment

We will look at how your child's arm functions.

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 3 of 17

Intelligence assessment

We will assess your child's visual construction skills and general intelligence.

Child questionnaires

We will ask your child to complete the CP Quality of Life questionnaire for children. It looks at social wellbeing, feelings about functioning, participation, emotional wellbeing and self-esteem, access to services, pain and impact of disability, and family health.

Parent questionnaires

We will ask you, depending on the age of your child, to complete questionnaires that focus on your child's behaviour.

- The Strengths and Difficulties Questionnaire (SDQ) looks at emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems and prosocial behaviour.
- The Behaviour Rating Inventory of Executive Function (BRIEF) looks at your child's ability to regulate their behaviour, such as to control impulses, to tolerate change and to regulate emotional responses appropriately. The BRIEF also looks at how your child's mind works, such as problem-solving strategies, working memory, ability to plan and organise, and to keep track of their behaviour.
- The Vineland Adaptive Behaviour Scales looks at your child's personal and social skills in everyday life.

Study Intervention

<u>Infusion</u>

Your child will need to come to the hospital for Visit 3 for the study treatment infusion.

During this visit the following procedures will occur:

- A nurse will use a numbing cream and insert an intravenous catheter (IV catheter, a needle) into a vein in your child's arm, hand or foot. This catheter will stay in your child's vein until they are ready to leave the hospital.
- Your child will be given medication to prepare them for the infusion. Some of the medication will go through the IV catheter, some can be by mouth (swallowed). The medications are:
 - To reduce the chance of allergic reaction
 - a) Hydrocortisone IV
 - b) Antihistamine (Phenergan or Zyrtec) IV or by mouth
 - To reduce pain

0

- a) a) Paracetamol by mouth
- To reduce nausea
 - a) Ondansetron by mouth
- If your child is blood group rhesus negative (Rh⁻, for example AB⁻ or O⁻), and receiving cord blood cells from a sibling who is blood group rhesus positive (Rh⁺), your child may need an injection of anti-rhesus D immunoglobulin (also known as Anti-D) so that your child's blood doesn't build up antibodies that could cause problems in the future. This injection will be through the IV catheter.
- A nurse will take a blood sample from your child.
- Your child will be given intravenous fluids through the catheter (sometimes called a 'drip'). The fluid keeps your child hydrated and helps your child's body to cope with the infusion. It will make them urinate more which gets rid of toxins in the body. The fluid will stay attached to your child's arm for 2 hours before the cord blood cell infusion. Your child will be able to move around during this time.

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 4 of 17

- When your child is ready and the cord blood cells arrive from the laboratory, your child will receive the product intravenously, through the catheter into a vein. The infusion will take around half an hour. The nurse will continue to give your child extra fluids through the catheter for 4 hours afterwards to look after your child, and will watch him/her carefully and call the doctor if needed.
- The nurse will take another blood sample 4 hours after the infusion to compare with the blood taken just beforehand.
- When your child is ready and the nurse has taken out the catheter, your child will be able to go home. Your child will not need to stay at the hospital overnight unless they have had an unusually bad reaction to the infusion.

Informing your GP

It is desirable that your child's local doctor be advised of your decision for your child to participate in this research project. If your child has a local doctor, we strongly recommend that you inform them of your child's participation in this research project.

1) Optional consent

We would like to provide information about the safety of cord blood cell infusions to an international registry called the Center for International Bone Marrow Transplant Research (CIBMTR) and to a local registry called the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR). The registries collect information about all bone marrow transplants and cord blood cell infusions from the hospitals involved in this study. Data from large numbers of patients receiving similar treatments in different hospitals is valuable because it can be analysed with more meaningful results than just looking at small numbers of patients from a single hospital or single clinical trial.

The CIBMTR is located at the Medical College of Wisconsin, Milwaukee, USA. This centre has been collecting information on worldwide allogeneic transplants and infusions since the early 1970s. The ABMTRR is located in St Vincent's Hospital Sydney, Australia and has collected data since 1992. Your child's name would not be on any information sent to the registries. The information will be coded with a unique identification number. A master file linking the identification number with your child's name will be stored in a password-protected file in the infusion hospital's transplant centre. The registries would collect information about your child's gender, date of birth and medical condition. We would also give information about the infusion, including the drugs used before, during and after, whether the infused cells engraft or are rejected by your child's body, any illness, infections or side-effects developed after the infusion begins and information about the cord blood unit itself. This information is already collected as part of the trial, but you can choose whether we send all the information to the CIBMTR and ABMTRR.

2) Optional Consent

We would like you to consider allowing us to send you information about new research projects related to this project. The information we send will give you full details about the project. It is your choice whether you agree to let your child take part in any future project or not.

4 Your responsibilities to the study

- Your child and a parent/guardian needs to be able to attend the infusion hospital for at least 7 visits and another two visits either at the hospital or in your community.
- Your child needs to be able to accept various needles for blood tests, cord blood cell infusion and hydration.
- Your child must be healthy to participate in this research study. The study doctor will examine your child and your child's blood to look for viruses or other signs of ill health. The study doctor will refer your child to appropriate health professionals if the examinations find anything that might indicate your child is not healthy, so that your child can receive professional advice and treatment if it is needed.

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 5 of 17

5 Other relevant information about the research project

There will be up to 12 children from around Australia taking part in this research study. Cord blood cell infusions may take place at two hospitals:

- 1. The Royal Children's Hospital Melbourne;
- 2. Lady Cilento Children's Hospital, Brisbane.

Other trial activities may take place at The Children's Hospital at Westmead, NSW, and at Monash Medical Centre in Melbourne.

6 Does the child have to take part in this research project?

Participation in any research project is voluntary. If you do not wish for your child to take part, they do not have to. If you decide that they can take part and later change your mind, you are free to withdraw your child from the project at any stage.

You do not need to tell us the reason why you or your child want to stop being in the project. However, please tell us if your child plans to leave the research study so that we can let you know if there are any health risks or special requirements linked to withdrawing. If your child leaves the study, we will use any information or samples already collected unless you tell us not to.

If you withdraw your child from the study after your child's cord blood has been transported from the cord blood bank where it is stored, the cord blood bank may not allow the cord blood to be returned to storage.

If you do decide that your child can take part, you will be given this Participant Information and Consent Form to sign and you will be given a copy to keep.

Your decision that your child can or cannot take part, or that they can take part and then be withdrawn, will not affect their routine treatment, relationship with those treating them, or their relationship with The Royal Children's Hospital Melbourne.

7 What are the alternatives to participation?

Your child does not have to take part in this research project to receive treatment at this hospital. The study doctor will discuss with you if other options are available.

8 What are the possible benefits of taking part?

We do not know whether there will be any benefit to your child if your child receives cord blood cells. We expect the main benefits of this study to be for others in the future. We hope the information we get will allow us and other researchers around the world to eventually determine the safety and effectiveness of stem cell infusion for children with cerebral palsy.

9 What are the possible risks and disadvantages of taking part?

Many participants in this study will not be able to continue with participation because 3 out of 4 siblings do not have matching blood.

Medical treatments often cause side effects. Your child may have none, some or all of the effects listed below, and they may be mild, moderate or severe. If your child has any of these side effects, or you are worried about them, talk with the study doctor. The study doctor will also be looking out for side effects.

There may be side effects that the researchers do not expect or do not know about and that may be serious. Tell the study doctor immediately about any new or unusual symptoms that your child gets.

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 6 of 17

Many side effects go away shortly after treatment ends. However, sometimes side effects can be serious, long lasting or permanent. If a severe side effect or reaction occurs, the study doctor may need to stop your child's treatment. Your child's study doctor will discuss the best way of managing any side effects with you.

Side Effect	How often is it likely to occur?	How severe might it be?	When might it happen?	How long might it last?
Anaphylaxis (allergic reaction)	Unlikely	Life-threatening	Soon after infusion	Temporary with treatment
Pain where the needle goes in	Likely	Mild	When the needle goes in	Temporary
Pain in the chest or back	Not known	Severe	During infusion	Temporary with treatment
Heart not beating in normal rhythm	Not known	Severe	Soon after infusion	Not known
Chills and/or Fever	Not known	Severe	Soon after infusion Days after infusion	Temporary with treatment
Headache	A mild reaction is moderately likely, severe is unlikely	Severe	Soon after infusion Days after infusion	Temporarily with treatment
Rash		Severe	Soon after infusion	Not known
Blood pressure rises or drops	A mild reaction is likely, severe is unlikely	Severe	Soon after infusion Days after infusion	Temporary with treatment
Nausea or vomiting	A mild reaction is likely, severe is unlikely	Severe	Soon after infusion	Temporary
Shortness of breath, cough	Not known	Moderate	Soon after infusion	Temporary with treatment
Not enough oxygen in blood	A mild reaction is likely, severe is unlikely	Severe	Soon after infusion	Temporary
Rigors (shaking chills)	A mild reaction is likely, severe is unlikely	Moderate	Soon after infusion	Temporary
Haemoglobin in urine	Not known	Moderate	Soon after infusion Days after infusion	Temporary
Infection in blood	Not known	Moderate	Days after infusion	Temporary with treatment
Graft-versus- Host disease	Very unlikely	Life-threatening	Within 3 months of infusion	It may be treatable and last only a short time, or it may last the rest of your child's life.
Developing antibodies to the sibling blood cells	Moderately likely	If your child needs a blood transfusion in the future, the antibodies might attack it If your child becomes pregnant in the future, the antibodies might attack the baby	Soon after infusion	Permanently

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 It is unlikely but possible that the cord blood cell infusion will change your child's functioning to the degree that your child may need different mobility aids after the infusion compared to the aids they are already using. The research study will not pay for these costs. Your family may have to pay for any new aids that are needed.

The following medications are given before the infusion to reduce the risk of allergic reaction and pain. These medications are available over the counter and their side effects are listed in Appendix 1.

- Antihistamime eg Phenergan or Zyrtec
- Hydrocortisone
- Paracetamol
- Ondansetron

If your child participates in this trial and receives cord blood cells, we will use <u>all</u> of his/her sibling's stored cord blood. <u>The sibling donor will be unable to receive an infusion of his/her own cord blood cells for possible life saving treatment in the future</u>. Your children would be dependent on finding matched cord blood through a public bank, should the need arise. If your child is unable to take part in the study and does not receive a cord blood cell infusion, his/her sibling's cord blood will remain in storage.

It is possible that this research study may uncover information about your child's movement disorder or general health that you were not aware of. We will also screen your child's blood for viruses and other signs of ill health that may prevent them participating in this study, and this test may find out information that you were not aware of. If your child needs medical care after these tests, we can refer your child to a doctor.

If you or your child becomes upset or distressed as a result of participation in the research questionnaires (e.g. CP QOL-Child), the study doctor will be able to arrange for counselling or other appropriate support. Any counselling or support will be provided by qualified staff who are not members of the research project team. This counselling will be provided free of charge.

Having a drug injected or blood taken may cause some discomfort, bruising, minor infection or bleeding. If this happens, it can be easily treated.

10 What will happen to your child's test samples?

The amount of blood collected at each visit is detailed below: please note 5 ml is equal to 1 teaspoon.

Blood collection	Blood volume needed	When is it taken?	What is it for?	Where does it go?	What happens to it afterwards?
1	10 ml	Visit 1	To match your child with the cord blood	Red Cross Transplantation Services	Transported and destroyed after matching
Sibling sample	2.7 ml	Visit 2	 To find out the sibling's blood group* 	RCH Melbourne pathology labs	Destroyed after matching
Maternal sample	2.7 mL	Visit 2	 To assess risk of contamination of cord blood* 	RCH Melbourne pathology labs	Transported and destroyed
2	19 ml	Visit 2	 To confirm the cord blood matches with your child To check that your child is healthy Pregnancy test if required 	 Red Cross Transplantation Services RCH Melbourne pathology labs 	Transported and destroyed after matching Destroyed

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8

3	11 ml	Visit 3 (before infusion)	• To compare with the blood sample taken afterwards	 RCH Melbourne pathology labs Research labs 	Destroyed Frozen, transported
4	8.2 ml	Visit 3 (after infusion)	 To compare with your child's blood before the therapy 	 Cyto-molecular diagnostics lab Research labs 	Frozen, transported and stored
5	8.2 ml	Visit 4	 To check for infection To check the cell types in your child's blood 	 RCH Melbourne pathology labs Cyto-molecular diagnostics lab Research labs 	Destroyed Frozen, transported
7	8.2 ml	Visit 5	 To look for inflammation To check the cell types in your child's blood 	 RCH Melbourne pathology labs Cyto-molecular diagnostics lab Research labs 	Destroyed Frozen, transported
8	7.2 ml	Visit 6	 To look for inflammation To check the cell types in your child's blood 	 RCH Melbourne pathology labs Cyto-molecular diagnostics lab Research labs 	Destroyed Frozen, transported
9	7.2 ml	Visit 7	 To look for inflammation To check the cell types in your child's blood 	 RCH Melbourne pathology labs Cyto-molecular diagnostics lab Research labs 	Destroyed Frozen, transported

* We may not need these samples, we hope to test the cord blood instead but if more testing is needed the study coordinator will contact you as soon as possible.

Samples of your child's blood obtained for the purpose of this research project will be transferred to the Cyto-molecular diagnostics research group at the Murdoch Childrens Research Institute (MCRI) for testing.

<u>The proposed blood tests include a screening test for HIV (also called the 'AIDS' virus) and</u> <u>Hepatitis.</u> This is because the study doctors need to know that your child is healthy enough to receive cord blood cell infusion. You and your child will receive information and counselling before the test. If a test shows your child has HIV or Hepatitis, follow-up counselling and medical advice will be provided. If the test results are positive, the study doctors are required by law to notify government health authorities. Signing the consent form means that you agree to your child having this testing; it will not be done without your consent.

Pregnancy test

If your child is a girl who has reached puberty and is able to have children, she will have a blood pregnancy test.

Girls must have a negative pregnancy test to be able to take part in this project.

3) Optional Consent

We would like to store samples of your child's blood from before and after the infusion, for future ethically-approved research studies related to stem cell treatment of cerebral palsy. **This would need a further 5 ml (a teaspoonful) of your child's blood at each blood collection.** We hope that when more information is known about stem cell treatment for cerebral palsy, we or other researchers in Australia will be able to test your child's samples in the future. If you consent, we will store your child's samples at the Biobanking Laboratory in the Murdoch Childrens Research Institute for an indefinite period of time. The samples will be stored using a special ID number. Your child's name will not be attached to the samples. We do not plan to

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 9 of 17

contact you or your child if the samples are used in future research, however you will be able to withdraw your child's samples at any time in the future if you choose. Your child's samples will not be sold by the Monash Medical Centre, however they may charge study doctors a fee to recover some of the costs of storing and administering the tissue samples.

Once your child's blood samples are transferred to the Murdoch Childrens Research Institute, The Royal Children's Hospital Melbourne will not be able to control whether the Murdoch Childrens Research Institute transfers the samples at some future date, however the Murdoch Childrens Research Institute will not knowingly transfer your child's samples to anyone who has expressed intent to sell the samples.

11 What if new information arises during this research project?

Sometimes during the course of a research project, new information becomes available about the treatment that is being studied. If this happens, the study doctor will tell you about it and discuss with you whether you want the participant to continue in the research project. If you decide to withdraw the participant, their study doctor will make arrangements for their regular health care to continue. If you decide that the participant can continue in the research project, you will be asked to sign an updated consent form.

Also, on receiving new information, the study doctor might consider it to be in the participant's best interests to withdraw them from the research project. If this happens, the doctor will explain the reasons and arrange for the participant's regular health care to continue.

12 Can your child have other treatments during this research project?

Whilst your child is participating in this research project, they may not be able to have treatments for their condition or for other reasons. It is important to tell the study doctor and the study staff about any treatments or medications the participant may be taking, including overthe-counter medications, vitamins or herbal remedies, acupuncture or other alternative treatments. You should also tell the study doctor about any changes to these during your child's participation in the research project. The study doctor should also explain to you which treatments or medications need to be stopped for the time your child is involved in the research project.

It may also be necessary for the participant to take medication during or after the research project to address side effects or symptoms that they may have. You will not need to pay for these medications during this study.

It is also important to tell us about any CP surgery your child has had, and to tell us about any other cell therapy your child has received.

Your child will not be assessed or receive the infusion within three months of having surgery or Botulinum toxin A injection. After the infusion, they will not be able to have Botulinum toxin A injection or surgery for 3 months. However, we do not want any participants to delay having a treatment that they need, so please discuss this with the study doctor.

Please fully disclose all relevant information.

13 What if I withdraw my child from this research project?

If you decide to withdraw your child from the project, please notify a member of the research team before you withdraw them. This notice will allow that person or the research supervisor to further discuss any health risks or special requirements linked to withdrawing.

If you do withdraw the participant during the research project, the study doctor and relevant study staff will not collect additional personal information, although personal information already collected will be kept to ensure that the results of the research project can be measured properly and to comply with law. You should be aware that data collected up to the time of Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 Page 10 of 17 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8

withdrawal will form part of the research project results. If you do not want this to happen, you must tell the study doctor before your child joins the research project.

14 Could this research project be stopped unexpectedly?

This research may be stopped for a variety of reasons. We may need to stop the cord blood cell infusion or total participation for your child for the following reasons:

- if we believe that it is in their best interest
- if your child has side effects from the infusion that are considered too severe
- if the research group needs to stop the study unexpectedly
- decisions made by local regulatory/health authorities

New information may become available that might affect your decision to let your child stay in the study. If we learn any new information, we will talk to you about it.

15 What happens when the research project ends?

After the research study is finished and all the information has been examined, the study team will send you a summary of the results from the whole trial. We can also send you a copy of your child's personal assessment results.

16 What will happen to information about your child?

By signing the consent form you consent to the study doctor and relevant research staff collecting and using personal information about your child for the research project. Any information obtained in connection with this research project that can identify your child will remain confidential. It will be disclosed only with your permission, or as required by law. Their information will be coded with a unique study identification number. All electronic and paper documents will be securely stored at the Murdoch Childrens Research Institute or at The Royal Children's Hospital Melbourne. Your child's information will only be used for the purpose of this research project.

Information about your child may be obtained from their health records held at this and other health services, for the purpose of this research. By signing the consent form, you agree to the study team accessing health records if they are relevant to your child's participation in this research project.

Information about your child's participation in this research project may be recorded in their health records.

Your child's health records and any information obtained during the research project are subject to inspection (for the purpose of verifying the procedures and the data) by the relevant authorities, the institution relevant to this Participant Information Sheet, The Royal Children's Hospital Melbourne, or as required by law. By signing the Consent Form, you authorise release of, or access to, this confidential information to the relevant study personnel and regulatory authorities as noted above.

As the participants in this project are under 18 years old, we must keep information until the youngest participant turns 25 years old. The research information may be destroyed or kept indefinitely in secure storage after this time.

It is anticipated that the results of this research project will be published and/or presented in a variety of forums. In any publication and/or presentation, information will be provided in such a way that your child cannot be identified, except with your permission.

Information about your child's involvement in this trial will be used in the future to help us plan other clinical trials of cord blood cell infusion for cerebral palsy. Any information used in this way will not identify your child.

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 11 of 17

In accordance with relevant Australian and/or Victorian privacy and other relevant laws, you have the right to request access to the participant's information collected and stored by the study team. You also have the right to request that any information with which you disagree be corrected. Please contact the study team member named at the end of this document if you would like to access the participant's information.

17 Compensation

If your child suffers any injuries or complications as a result of this research project, you should contact the study team as soon as possible and you will be assisted with arranging appropriate medical treatment for your child. If your child is eligible for Medicare, they can receive any medical treatment required to treat the injury or complication, free of charge, as a public patient in any Australian public hospital.

By signing this consent form, you are not giving up any legal rights to seek to obtain compensation for injury.

18 Who is organising and funding the research?

This research has been initiated by the Murdoch Childrens Research Institute, Cerebral Palsy Alliance, The Royal Children's Hospital Melbourne, Monash Health, Hudson Institute of Medical Research, The Children's Hospital at Westmead, Lady Cilento Children's Hospital Brisbane, and The University of Queensland.

The research is primarily funded by Cell Care Australia and the Cerebral Palsy Alliance. Whilst these organisations are funding this study, they are also part of the research team, and we have research agreements in place to manage this arrangement.

No member of the research team will receive a personal financial benefit from your child's involvement in this research project (other than their ordinary wages).

There are no additional costs associated with participation in this research project, nor will you or your child be paid. All medication, tests and medical care required as part of the research project will be provided to your child free of charge.

You will be assisted with the expenses for any travel, accommodation, parking, meals and other expenses associated with the research project visits.

19 Who has reviewed the research project?

All research in Australia involving humans is reviewed by an independent group of people called a Human Research Ethics Committee (HREC). The ethical aspects of this research project have been approved by the HREC of The Royal Children's Hospital, Melbourne.

This project will be carried out according to the *National Statement on Ethical Conduct in Human Research (2007)*. This statement has been developed to protect the interests of people who agree to participate in human research studies.

20 Further information and who to contact

The person you may need to contact will depend on the nature of your query.

If you want any further information concerning this project or if your child has any medical problems which may be related to their involvement in the project (for example, any side effects), you can contact the principal study doctor, Professor Dinah Reddihough, on (03) 9345 5898 or any of the following people:

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 12 of 17

Clinical contact person

Name	Dr Francoise Mechinaud
Position	BMT Transplant Doctor
Telephone	(03) 9345 5522
Email	francoise.mechinaud@rch.org.au

For matters relating to research at the site at which your child is participating, the details of the local site complaints person are:

Complaints contact person

Position	Director
HREC name	Research Ethics & Governance, The Royal Children's Hospital Melbourne
Telephone	(03) 9345 5044
Email	Rch.ethics@rch.org.au

If you have any complaints about any aspect of the project, the way it is being conducted or any questions about being a research participant in general, then you may contact:

Reviewing HREC approving this research and HREC Executive Officer details

Reviewing HREC Name	The Royal Children's Hospital HREC
HREC position	Director
Telephone	(03) 9345 5044
Email	Rch.ethics@rch.org.au

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 13 of 17

Consent Form – Parent/Guardian

Title	Safety study of sibling cord blood cell infusion to children with cerebral palsy
Short Title	Stem Cells in Umbilical Blood Infusion for CP (SCUBI-CP)
HREC ID	HREC/14/RCHM/38
Principal Investigator	Prof Dinah Reddihough
Location	The Royal Children's Hospital Melbourne

Declaration by Parent/Guardian

I have read the Participant Information Sheet or someone has read it to me in a language that I understand.

I understand the purposes, procedures and risks of the research described in the project.

I give permission for the child's doctors, other health professionals, hospitals or laboratories outside this hospital to release information to The Royal Children's Hospital Melbourne concerning the child's disease and treatment for the purposes of this project. I understand that such information will remain confidential.

I have had an opportunity to ask questions and I am satisfied with the answers I have received.

I freely agree to the child participating in this research project as described and understand that I am free to withdraw them at any time during the research project without affecting their future health care.

I freely agree to the full use of my child's cord blood for this research project as described and understand that I am free to withdraw my agreement at any time before the cord blood has been used.

I understand that I will be given a signed copy of this document to keep.

🗌 l do	🗌 l do not	consent to the transfer of information about my child's cord blood cell infusion to the Center for International Bone Marrow Transplant Research in the USA and to the Australasian Bone Marrow Transplant Recipient Registry
🗌 l do	🗌 l do not	consent to be contacted about future research projects that are related to this project
🗌 l do	🗌 l do not	consent to the collection of an extra 5 mls of blood (one teaspoonful) of my child's blood each time blood is collected. This will be stored at the Biobanking Laboratory in the Murdoch Childrens Research Institute for an indefinite period and used for future ethically approved research into cord blood cells for cerebral palsy

Signature of Parent/Guardian	Date
Name of Parent/Guardian	
Name of Child (please print)	

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 14 of 17

Name of Witness* to Parent/Guardian's Signature (please print)		
Signature	Date	

* Witness is <u>not</u> to be the investigator, a member of the study team or their delegate. In the event that an interpreter is used, the interpreter may <u>not</u> act as a witness to the consent process. Witness must be 18 years or older.

Declaration by Study Doctor/Senior Researcher[†]

I have given a verbal explanation of the research project, its procedures and risks and I believe that the parent/guardian has understood that explanation.

Name of Study Doctor/ Senior Researcher [†] (please print)		
Signature	Date	

[†] A senior member of the research team must provide the explanation of, and information concerning, the research project.

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 15 of 17

Appendix 1: Risks and side effects of over-the-counter medications used in this study In large doses or with long term use:

Risks	and side effects of Phene	rgan		
	Common	Serious		Very Serious
 sto los na dia tire res diz 	y mouth, nose & throat omach upset as of appetite nusea or vomiting arrhoea or constipation edness or sleepiness stlessness zziness urred vision	 fever difficulty breathing irregular heart beat jaundice - yellow tinge to skin or eyes tremors or convulsions tinnitus - buzzing, hissing, ringing or other persistent noise in the ears seizures (fits) hallucinations nervousness and irritability anxiety twitching or jerking muscles 	•	wheezing or difficulty breathing swelling of the face, lips, tongue or other parts of the body skin rashes
• Ri	sks and side effects of Zy	rtec		
	ommon	Serious	•	Very Serious
 sto los na dia tire res diz blu 	y mouth, nose & throat omach upset as of appetite nusea arrhoea or constipation edness or sleepiness stlessness zziness urred vision usebleed	 difficulty breathing irregular heart beat hepatitis or liver problems seizures (fits) nervousness and irritability problems with eyesight twitching or jerking muscles 	•	wheezing or difficulty breathing swelling of the face, lips, tongue or other parts of the body allergic reaction

Risks and side effects of Paracetamol		
Common	Serious	Very Serious
 Nausea and vomiting Stomach pain Indigestion Sweating 	 Skin rashes Painful red areas with blisters and peeling layers of skin which may be accompanied by fever and/or chills Severe blisters and bleeding in the lips, eyes, mouth, nose and genitals Hepatitis (symptoms include loss of appetite, itching, yellowing of the skin and eyes, light coloured bowel motions, dark coloured urine) 	 shortness of breath wheezing or difficulty breathing swelling of the face, lips, tongue or other parts of the body rash, itching or hives on the skin

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8 Page 16 of 17

Common	Serious	Very Serious
	 Problems with your growth. muscle weakness or loss of muscle mass 	 Allergic reactions, e.g. skin rash, itching, difficulty breathing, wheezing or coughing bone fractures or muscle pain severe stomach pain, nausea and vomiting vomiting blood or material that looks like coffee grounds, bleeding from the back passage, black sticky bowel motions (stools) or bloody diarrhoea convulsions or fits blurred or distorted vision or loss of vision, eye infections red, purple or brown patches on your skin problems with your back, including pain or weakness loss of sensation or problems with your reflexes (slow or too fast) bouts of anxiety and headaches, sweating, palpitations, dizziness, a feeling of weakness, nausea, vomiting, diarrhoea, dilated pupils and blurring vision, stomach pains, and raised blood pressure. These could b symptoms of a rare tumour of the adrenal gland, which sits

Common
anxiety difficulty having a bowel movement dry mouth general feeling of discomfort or illness hyperventilation irritability restlessness shaking trouble sleeping

Master Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 9 RCHM Site Parent/Guardian Information Sheet/Consent Form 15/03/2017, Version 8

Page 17 of 17